Page not found or access was denied

From 17–19 November, ICON will be at the 18th EBF Open Symposium at the Hyatt Regency Barcelona Tower. ICON is excited to contribute to the scientific dialogue at the 18th EBF Open Symposium, taking place 17–19 November...

When Congress deadlines, extension and notifications dates change, will you know? PubsHub Journals & Congresses incorporates user-defined watchlists that can send alerts in the case of deadline updates, extensions and ot...

How do glycosylation patterns of biopharmaceuticals change once they enter circulation, and what could those changes tell us about their clinical behaviour? Join our webinar hosted by Bioanalysis Zone to explore an LC-HR...

Navigating the clinical complexity of chronic disease requires integrating multimodal datasets and advanced analytics. Learn how combining AI-driven patient stratification and toxicity prediction with deep therapeutic ex...

We’re proud to share that ICON is the only CRO named a 2027 BioSpace Best Place to Work, placing in the Top 10 in the large employer category. This recognition reflects the views of life sciences professionals and consi...

ADCs have broad potential as targeted cancer therapies, but predicting which patients will benefit is a significant challenge. A single ADC combines three therapeutic components whose efficacy is then shaped by the tumor...

Emerging approaches to first-in-human studies are helping sponsors obtain meaningful clinical insights sooner through integrated study designs, stronger patient engagement, and strategic biomarker implementation. In thi...

As understanding of multi-system disease grows, so does interest in earlier disease intervention. However, development and commercialisation pathways for early-intervention therapies remain complex and challenging. Learn...

Complex clinical supply models shouldn’t be designed only for the ideal pathway. For cell and gene therapy studies, a delay, identity mismatch, condition issue, failed manufacture or unavailable interface can affect an i...

Staying up to date with global regulatory changes can be challenging. ICON's Global Regulatory Intelligence Newsletter brings together the latest updates from regulatory authorities around the world in a concise, easy-t...

Latest issue out now. Regulatory requirements continue to evolve across global markets. Keeping pace with changes from the FDA, EMA, MHRA, PMDA, NMPA and other health authorities is critical for successful product deve...

New research published in Drug Metabolism and Disposition offers important insights into the clinical pharmacology of remibrutinib, an oral, highly selective BTK inhibitor approved in the United States, China, the Europe...